Parameter
|
Base case value
|
High value
|
ICER
|
Low value
|
ICER
|
PFS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %)
| |
50 %
|
1,384 €
|
150 %
|
Dominant
|
PFS: BEV plus PACL (−50 %; +50 %)
| |
50 %
|
Dominant
|
150 %
|
Dominant
|
PFS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %)
| |
50 %
|
26,091 €
|
150 %
|
Dominant
|
PFS: BEV plus CAPE (−50 %; +50 %)
| |
50 %
|
Dominant
|
150 %
|
Dominant
|
OS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %)
| |
50 %
|
€11,251 €
|
150 %
|
Dominant
|
OS: BEV plus PACL (−50 %; +50 %)
| |
50 %
|
Dominant
|
150 %
|
Dominant
|
OS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %)
| |
50 %
|
17,104 €
|
150 %
|
Dominant
|
OS: BEV plus CAPE (−50 %; +50 %)
| |
50 %
|
Dominant
|
150 %
|
5,876 €
|
Fixed post-progression survival (6–48 months)
|
12
|
6
|
Dominant
|
48
|
Dominant
|
Utility: pre-progression (0.36; 0.90)
|
0.773
|
0.36
|
Dominant
|
0.90
|
Dominant
|
Utility: post-progression (0.2; 0.97)
|
0.496
|
0.22
|
Dominant
|
0.97
|
Dominant
|
Pre-progression background costs (50 €; 150 €)
|
95.16 €
|
50.00 €
|
Dominant
|
150 €
|
Dominant
|
Post-progression background costs (500 €; 1500 €)
|
1,057.41 €
|
500.00 €
|
Dominant
|
1,500 €
|
Dominant
|
Adverse event costs: EVE plus EXE (38 €; 133 €)
|
62 €
|
37.89 €
|
Dominant
|
133 €
|
Dominant
|
Adverse event costs: BEV plus PACL (4.92 €; 34 €)
|
5.14 €
|
4.92 €
|
Dominant
|
34 €
|
Dominant
|
Adverse event costs: BEV plus CAPE (0.50 €; 34 €)
|
1 €
|
0.50 €
|
Dominant
|
34 €
|
Dominant
|
Adverse event disutilities: EVE plus EXE (0.011; 0.04)
|
−0.029
|
−0.011
|
Dominant
|
−0.04
|
Dominant
|
Adverse event disutilities: BEV plus PACL (0.005; 0.069)
|
0.027
|
−0.005
|
Dominant
|
−0.069
|
Dominant
|
Adverse event disutilities: BEV plus CAPE (0.005; 0.069)
|
−0.0031
|
−0.002
|
Dominant
|
−0.069
|
Dominant
|
Adverse events: unknown disutility assumption (−0.01; −0.10)
|
−0.05
|
−0.013
|
Dominant
|
−0.100
|
Dominant
|
BOLERO II Central PFS included
|
Without
| | |
With
|
Dominant
|
Fixed post-progression survival applied
|
Without
| | |
With
|
Dominant
|
Dose intensity included
|
Without
| | |
With
|
Dominant
|
Drug cost: EVE plus EXE vs. BEV plus PACL (2000 €; 5000 €)
|
2,447.75 €
|
2000 €
|
Dominant
|
5,000 €
|
324,159 €
|
Drug cost: BEV plus PACL (2000 €; 5000 €)
|
3,806.42 €
|
2000 €
|
151,243 €
|
5,000 €
|
Dominant
|
Drug cost: EVE plus EXE vs. BEV plus CAPE (2000 €; 5000 €)
|
2,447.75
|
2000 €
|
Dominant
|
5,000 €
|
4,082,144 €
|
Drug cost: BEV plus CAPE (2000 €; 5000 €)
|
3,510.97€
|
2000 €
|
3,539,497 €
|
5,000 €
|
Dominant
|
Extrapolation method (EVE plus EXE versus comparator)
|
Exponential, endpoint (PACL)
|
Dominant
|
Exponential, endpoint (CAPE)
|
Less effective
|
Gompertz (PACL)
|
Dominant
|
Gompertz (CAPE)
|
Less effective
|
Exponential, curve (PACL)
|
Dominant
|
Exponential, curve (CAPE)
|
Less effective
|
Log-logistic(PACL)
|
Dominant
|
Log-logistic (CAPE)
|
Dominant
|